Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456485 | 0.81 | FADS1 (0.51) | FADS1CYP11B1CYP11B2SCN5AAHR | |
| SCHEMBL18135592 | 0.79 | CYP11B1 (0.48) | FADS1CYP11B1CYP11B2SCN5ACYP19A1 | |
| SCHEMBL10012248 | 0.74 | HSD17B10 (0.50) | — | |
| SCHEMBL1318734 | 0.70 | ABL1 (0.41) | CYP11B1CYP11B2GABRA1GABRB2 | |
| SCHEMBL16541131 | 0.68 | FADS1 (0.39) | FADS1CYP11B1CYP11B2SCN5ACYP19A1 | |
| SCHEMBL13946402 | 0.68 | ABL1 (0.37) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL19723593 | 0.65 | ANO1 (0.38) | FADS1CYP11B1CYP11B2GABRA1GABRB2 | |
| SCHEMBL23994268 | 0.65 | RXFP1 (0.41) | FADS1AHR | |
| SCHEMBL15013578 | 0.64 | SCN5A (0.42) | CYP11B1CYP11B2SCN5AAHR | |
| SCHEMBL29381505 | 0.64 | ENPP1 (0.37) | CYP11B1CYP11B2CYP19A1GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | FADS1 3330/4885CYP11B1 3532/4885CYP11B2 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.